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ORIGINAL RESEARCH ARTICLE
Gestational diabetes mellitus in Greenland: a national
study of prevalence and testing efficacy
Michael Lynge Pedersen1,2*, Jesper Olesen2,
Marit Eika Jørgensen3,4 and Peter Damm5
1Greenland Center of Health Research, Institute of Nursing and Health Science, University of Greenland,
Nuuk, Greenland; 2Queen Ingrid Primary Health Care Center, Nuuk, Greenland; 3Steno Diabetes Center,
Gentofte, Denmark; 4National Institute of Public Health, Southern Denmark University, Denmark; 5Center for
Pregnant Women with Diabetes, Department of Obstetrics, Rigshospitalet, University Hospital of
Copenhagen, Copenhagen, Denmark
Background. Within the last 20 years, the prevalence of gestational diabetes mellitus (GDM) has been
reported to be increasing worldwide in correlation with ethnic and geographic variations. The actual
prevalence of GDM throughout all of Greenland remains unknown.
Objective. The aim of this study was to estimate the prevalence of GDM among Greenlanders and non-
Greenlanders living in Greenland and to estimate the efficacy of testing for GDM.
Design. This study was performed as an observational, cross-sectional study including all women with
permanent address in Greenland who had given birth to a singleton during 2014. The prevalence of GDM
was calculated as the proportion of all pregnant women tested with a 75-g 2-h glucose tolerance test who had
a 2-h capillary whole-blood glucose value of 8.5 mmol/l or above. Testing efficacy was calculated as the
proportion of women who fulfilled the testing criteria who were actually tested in Greenland in 2014.
Results. A total of 794 women (727 Greenlanders and 67 non-Greenlanders) were included in the study. The
prevalence of GDM among tested women was 3.3% (confidence interval, CI: 0.95.6) among Greenlanders
and 12.5% (CI: 025.7) among non-Greenlanders, corresponding, respectively, to 1.0% (CI: 0.31.3) and
4.5% (CI: 09.4) of all singleton pregnancies in Greenland in 2014. The overall testing efficacy was 69.0%
among all eligible residents of Greenland and 85.1% among eligible residents in the capital city, Nuuk.
Conclusion. In conclusion, the prevalence of GDM seems quite low in Greenland. Although diagnostic testing
activity has improved within the last 6 years, still around one-third of all pregnant women in all Greenland
fulfilling the testing criteria were not tested. Universal testing for GDM may be needed to improve testing of
GDM in Greenland.
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G
estational diabetes mellitus (GDM) is defined
as hyperglycaemia diagnosed during pregnancy
(1). GDM is a serious condition associated with
maternal and offspring complications like preeclampsia,
shoulder dystocia, caesarean delivery, macrosomia, neonatal
hypoglycaemia and hyperbilirubinaemia (25). Women di-
agnosed with GDM have an increased risk at around
50% of developing diabetes later in life (6,7). Also,
offspring of women with GDM have increased risk of
developing obesity and diabetes as children or in adult-
hood (711). The prevalence of GDM has been reported to
be increasing worldwide within the last 20 years (12,13),
and the offspring risk of developing obesity and diabetes
may contribute to the worldwide epidemic of these con-
ditions (12). Both ethnic and geographic variations re-
lated to the prevalence of GDM have been reported (13).
Prevalence estimates around 26% have been reported in
Europe with a trend towards higher prevalence in southern
Europe (13). Observations from Australia and the
United States report a higher prevalence of 58% among
Asians, Hispanics, Africans (12,13) and among Yupik Inuit
(14). Onlyone study has been performed investigating GDM
among Greenlanders in Greenland where the prevalence of
diabetes and obesity has been increasing over the last two

International Journal of Circumpolar Health 2016. # 2016 Michael Lynge Pedersen et al. This is an Open Access article distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium
or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
1
Citation: Int J Circumpolar Health 2016, 75: 32167 - http://dx.doi.org/10.3402/ijch.v75.32167
(page number not for citation purpose)
decades (1517). A low prevalence of GDM was pre-
viously reported; however, that study was relatively small,
and only inhabitants of the largest city of Greenland,
Nuuk, were included in the study (15). Thus, the nation-
wide prevalence of GDM in Greenland remains unknown.
Identifying women with GDM is important since appro-
priate glycaemic control during pregnancy can reduce
adverse perinatal outcomes (18,19). GDM is most often
asymptomatic and must be diagnosed by testing with an
oral glucose tolerance test (OGTT) (13,20). Testing
practices for GDM are inconsistent worldwide, even across
European countries (13). Practices range from universal
testing of all pregnant women to testing on a case-by-case
basis according to clinician or patient decisions (13). In
Greenland, testing for GDM is performed in high-risk
cases following the same criteria used in Denmark (21).
The testing efficacy in the 2008 study in Nuuk was reported
as suboptimal (15). However, the actual testing efficacy for
all of Greenland remains unknown. Thus, the aim of this
study was to estimate the prevalence of GDM  as well as
the testing efficacy  on a population-based scale including
all pregnant women who gave birth in Greenland in 2014.
Material and methods
This study was performed as an observational, cross-
sectional study based on the review of register data and
medical records.
Greenland is the biggest island in the world covering
approximately 2 million km2. The 56,000 inhabitants live
in 16 towns and approximately 60 settlements along the
coastline. Healthcare is delivered by one united public
healthcare system, free of charge to anyone with a per-
manent address in Greenland. Around half of all birth
deliveries in Greenland take place in the capital, Nuuk,
where the only obstetric department in Greenland is
located. Pregnant women experiencing complications
during pregnancy are referred to Nuuk. The remaining
births take place locally at small hospitals in smaller towns
and settlements. Prenatal care including first prenatal care
is performed by midwives in Nuuk and in some of the
larger towns in Greenland. In settlements and towns
without midwives, prenatal care is performed by other
healthcare professionals, by visiting midwives or the
pregnant women visiting towns with midwives. At all
settings prenatal care and medical information are docu-
mented in a systemized perinatal record. All births in
Greenland are reported to the Chief Medical Officer
(CMO) in Greenland.
The testing criteria and use of 2-h blood glucose values
follow the guidelines published by the Danish Society
of Obstetrics and Gynaecology in 2014 (22). The choice
to test for GDM is based on any one of the following
criteria: overweight (pre-pregnant body mass index (BMI)
]27 kg/m2), family history of diabetes among first-degree
relatives or grandparents, previous delivery of an infant
with a birth weight ]4,500 g and GDM during earlier
pregnancies. Finally, all pregnant women with glucosuria
are tested. Testing is performed using a 75 g OGTT at
28 gestational weeks. In addition, an OGTT is performed
at 18 gestational weeks if more than one risk factor is
present or if GDM was observed in a former pregnancy.
Diagnosis of GDM in Greenland is based on capillary
blood examined 2 h after the administration of glucose.
All women who had given birth in Greenland in 2014
were identified from the register held by the CMO.
Information about maternal age, country of birth, parity,
gestational age (GA) at delivery, mode of delivery, off-
spring sex, and birth weight and length was available for
all the women. In addition, information about maternal
weight, height, the results of examination of urine for
glucose, former pregnancies, family history of diabetes,
and smoking and alcohol use was obtained from the
perinatal records. Results from the OGTT were collected
from information recorded on the laboratory cards used
in Greenland. Women born in Greenland were considered
as Greenlanders, whereas women born outside Greenland
were considered as non-Greenlanders. Only women with a
singleton pregnancy were included in this study. Women
with pre-gestational diabetes and women treated with oral
steroids were excluded from the study.
The OGTT was performed in fasting, pregnant women
with the administration of 75 g pure glucose diluted in
water. Capillary blood was examined 2 h after the admini-
stration for glucose using a portable Hemocue† Glucose
201System (AB, Angelholm, Sweden), which was cali-
brated weekly. GDM was defined according to the Inter-
national Association of Diabetes and Pregnancy Groups
(IADPSG) recommendations on the Diagnosis and Clas-
sification of Hyperglycaemia in Pregnancy using only a
2-h (venous plasma) value of 8.5 mmol/l or above (20).
Thus, all women with a 2-h capillary whole-blood glu-
cose measurement of 8.5 mmol/l or above were considered
having GDM though assuming an acceptable agreement
between glucose measured in capillary whole blood and
venous plasma (23).
BMI was based on the subject’s self-reported weight and
height before pregnancy. The women were considered to be
smokers if they reported any tobacco smoking at the first
prenatal visit and were considered to be alcohol users if any
alcohol use was reported at the first prenatal visit. Delivery
was considered vaginal unless a caesarean section had been
performed. Women without a history of former delivery of
a child at GA at or above 28 weeks were classified as
nulliparous. GA was based on the subject’s self-reported
last menstrual period (LMP). In cases where LMP was
unknown and in cases where an ultrasound-based GA
calculation deviated 2 weeks or more from the LPM-based
GA, the ultrasound-based GA was used.
The prevalence of GDM was calculated as the pro-
portion of women with GDM among women screened
Michael Lynge Pedersen et al.
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with OGTT, and all women giving birth in Greenland
during 2014 were included in the study. The efficacy in the
testing procedure was determined as the proportion of
women meeting the testing criteria (see above) that were
actually tested with at least one OGTT. Ninety-five percent
confidence intervals (CI) were used in the study. Variables
were described using medians and interquartile range.
Medians were compared using MannWhitney U test.
Logistic regression was used to study the association
between Greenlanders and non-Greenlanders and GDM,
adjusting for age. Frequencies were compared using
Fischer’s exact test. A two-sided p-value below 0.05 was
used as the level of significance. Statistical analyses were
performed using SPSS statistical software, version 23.0
(Norusis; SPSS Inc., Chicago, IL).
The study was approved by The Ethics Committee
for Medical Research in Greenland and the Agency of
Health and Prevention in Greenland.
Results
In total, 794 women (727 Greenlanders and 67 non-
Greenlanders) giving birth to a singleton in Greenland
during 2014 were identified from the CMO’s register
and included in the study. None of the women gave birth
more than once during the study period. No cases were
excluded due to pre-existing diabetes or treatment with
oral steroids prior to pregnancy. Perinatal records with
additional information about the pregnancy were identi-
fied in 620 cases (78%), while the remaining 174 perinatal
journals could not be located.
Basic characteristics for the women are shown in
Table I. Greenlanders were younger, shorter, more frequent
smokers, had higher parity, gave birth at a lower GA and
less often by caesarean sections. Risk factors for GDM,
testing proportion and prevalence of GDM are shown in
Table II. In total, 49.4% (303/613) of the women presented
at least one of the five risk factors for GDM with BMI
above 27 kg/cm2 as the most prevalent risk factor observed
in one-third of all women. The testing efficacy among
women with at least one risk factor was 69.0% (209/303)
for all pregnant women in Greenland and 85.1% for
Nuuk residents. The testing efficacy among Greenlanders
was 67.6% (188/278), which was lower than the 84.0%
(21/25) among non-Greenlanders (p0.047). In total,
30.1% (239/794) of all the women were tested during
pregnancy. The crude prevalence of GDM among tested
women was 4.2% (CI: 1.66.7). The prevalence among
tested Greenlanders was 3.3% (CI: 0.95.6) and among
tested non-Greenlanders was 12.5% (CI: 025.7) (p0.02)
corresponding to a prevalence of 1.0% (CI: 0.31.7) and
4.5% (CI: 09.4) (p0.019) of all women included in
the study. However, when adjusting for age by logistic
regression, no difference was found between Greenlanders
and non-Greenlanders (Table II).
Discussion
The overall prevalence of GDM among all tested women
who gave birth to a singleton in 2014 in Greenland was
estimated to be 4.2% (CI: 1.66.7). No difference in
prevalence of GDM was observed between Greenlanders
and non-Greenlanders when adjusting for age. Around
one-third of all women fulfilled the testing criteria for
GDM used in Greenland, and of those, 69.0% were
actually tested. The highest testing efficacy (85.1%) was
achieved among Nuuk residents.
A major strength of this study is that it is the first study
to include all pregnancies in Greenland and only the
second study on GDM performed in Greenland. However,
limitations exist and the results must be interpreted with
some reservations. The true overall prevalence of GDM
among all pregnancies in Greenland is most likely lower
than the 4.2% reported among all screened women because
these women represent women with at least one risk factor
for GDM. On the contrary, the prevalence among all
Table I. Basic characteristics of pregnant women in Greenland 2014
Characteristics and variables Greenlanders Median (IQR) N727 Non-Greenlanders Median (IQR) N67 p
Maternal age (years) 26 (8.0) 31 (6.0) B0.001
Height (cm)a 161 (9.0) 167 (12.0) 0.014
Weight before pregnancy (kg)b 65 (19.3) 64 (24.5) 0.784
BMI (kg/m2)c 24.5 (6.9) 23.7 (5.5) 0.696
Gestational age at delivery (days) 274 (12.0) 277 (13.3) 0.008
Birth weight (g) 3,575 (725) 3,495 (770) 0.798
Birth length (cm) 51 (3.0) 52 (3.0) 0.173
Nulliparous (%) 39.9 (289/724) 53.7 (36/67) 0.037
Vaginal delivery (%) 93.5 (680/727) 77.6 (52/67) B0.001
Smoking during pregnancy (%) 55.3 (316/571) 23.3 (14/60) B0.001
Alcohol during pregnancy (%) 3.0 (17/570) 1.7 (1/60) 0.999
Male offspring (%) 51.4 (374/727) 46.3 (31/67) 0.445
aN561, bN565, cN559, p-value B0.05 in bold, inter quartiles range (IQR).
Gestational diabetes in Greenland
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women must be higher than the 1.3% reported in this study
because not all women with a least one risk factor were
screened. In addition, GDM may also be found among
women without any known risk factors. Thus, changing
testing strategy among Aboriginals in Australia from
selective risk-factor-based screening to universal screening
resulted in an increase of 40% in prevalence of GDM,
underlining that GDM can occur among women without
risk factors (24). A recent study identified a common
mutation in TBC1D4 causing muscle-tissue-specific in-
sulin resistance and postprandial hyperglycaemia (25).
This variant accounts for around 15% of all diabetes
among Greenlanders and is not associated with usual
diabetes risk factors. This mutation in TBC1D4 is most
likely related to high risk of GDM (25). Thus, also pre-
gnant women without other known risk factors for GDM
may have the mutation and, thus, actually be at high risk
of GDM. However, with a risk-factor-based test strategy,
these women will not be offered an OGTT, and conse-
quently, cases of GDM may remain undiagnosed.
Another limitation is that not all the perinatal records
could be located, leading consequently to incomplete
information about risk factors for some of the pregnancies.
Still, 78% of the perinatal records were included, and
we have no reason to believe that the missing perinatal
records represent a systematic selection bias. In addition,
the estimated prevalence of GDM was not affected by
the missing perinatal records because information about
OGTT was available for all women in the laboratory
system. A total of 9.3 and 3.2% of Greenlandic and non-
Greenlandic women, respectively, had glycosuria. How-
ever, only one-third of these women underwent testing,
suggesting that GDM is underestimated for this risk factor
criterion. Also, in this study only 2-h capillary whole-blood
glucose values could be included since no laboratory in
Greenland measures glucose concentrations in venous
plasma. Thus, it is likely that some women with GDM
according to IADPSG (20) thresholds for fasting or 1-h
plasma glucose tests have not been diagnosed by the
2-h capillary whole-blood glucose concentrations alone.
Consequently, the prevalence reported in this study might be
underestimated and GDM under-diagnosed in Greenland
because diagnostic testing is not universal, but risk factor
based, and does not include a fasting or 1-h glucose value
test.
The prevalence reported in this study is similar to
the prevalence (4.3%) reported among Greenlandic
women who gave birth in Nuuk during 2008 (15). The
prevalence of GDM in Greenland seems to be compar-
able internationally with northern Europe with its pre-
valence at 24% (13). Also, the prevalence of GDM
among Greenlanders seems comparable with or even
lower than prevalence among non-Hispanic white
people in the United States (2.96.9%) and non-Aboriginal
people in Australia (3.17.5%) (12). Higher prevalence has
been reported among Native Americans, Asians, Hispanics
and African-Americans living in the United States than
among non-Hispanic white people and among Abo-
riginals compared with non-Aboriginals in Australia
(12,13). This is in contrast to this study where the
lowest crude prevalence was observed among the Green-
landers. Yet, no difference was observed when adjusting
for age.
A country-wide test efficacy in Greenland of 69.0%
reported in this study, and the 85.1% in Nuuk is much
higher than reported in Nuuk in 2008 (54%). This may
reflect the increased awareness of diabetes in Greenland
where the prevalence of diagnosed diabetes has also been
Table II. Risk factors, testing proportions and prevalence of gestational diabetes (GDM) among women included in the study
Risk factor
Greenlanders
(%) (n/N)
Non-Greenlanders
(%) (n/N) p
All women
(%) (n/N)
Proportion
tested (%)
Diabetes in former pregnancy 0.2 (1/566) 0 (0/60) 0.999 0.2 (1/626) 100 (1/1)
Family history of diabetes 14.1 (80/566) 23.7 (14/59) 0.056 15.0 (94/625) 67.0 (63/94)
Previous delivery of an infant with
a birth weight ]4,500 g
3.9 (22/563) 1.7 (1/59) 0.714 3.7 (23/622) 87.0 (20/23)
BMI]27 kg/m2 35.3 (196/555) 20.0 (12/59) 0.021 33.9 (208/614) 71.6 (149/208)
Glycosuria 9.3 (56/603) 3.2 (1/31) 0.348 9.0 (57/634) 33.3 (19/57)
At least one risk factor 50.1 (278/555) 43.1 (25/58) 0.336 49.4 (303/613) 69.0 (209/303)
At least one risk factor Nuuk residents 45.1 (74/164) 51.3 (20/39) 0.592 46.3 (94/203) 85.1 (80/94)
OGTT performed all women 29.6 (215/727) 35.8 (24/67) 0.330 30.1 (239/794) 30.1 (239/794)
GDM all women (95% CI) and (n/N) 1.0 (0.31.7)
(7/727)
4.5 (09.4)
(3/67)
0.121* 1.3 (0.52.0)
(10/794)

GDM tested women (95% CI) and (n/N) 3.3 (0.95.6)
(7/215)
12.5 (025.7)
(3/24)
0.161* 4.2 (1.66.7)
(10/239)

*Age-adjusted, p-value B0.05 in bold, gestational diabetes mellitus (GDM).
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steadily increasing within the last decade (16,17). The
higher test efficacy in Nuuk most likely reflects that the
only obstetrics department in Greenland is also situated
in Nuuk. The minor, geographically isolated healthcare
clinics without specialists outside of Nuuk are challenged
in the delivery of all kinds of primary healthcare including
the care of patients normally dealt with by specialists. Also,
lack of healthcare professionals and the employment of
short-term, temporary workers challenge the continuity
in delivering healthcare locally. Routine, universal testing
for GDM might help increasing the test efficacy, but this
decision has to be balanced with the difficulty of
performing the cumbersome OGTT and the relatively
low prevalence of GDM among Greenlanders reported in
this study, which thus might not warrant the effort.
In conclusion, the prevalence of GDM seems quite low
in Greenland. Although diagnostic testing activity has
improved within the last 6 years, around one-third of all
pregnant women in all Greenland fulfilling the testing
criteria were still not tested. Universal testing for GDM
may be needed to improve testing of GDM in Greenland.
Key finding
The prevalence of GDM seems low among Greenlanders
in contrast to reports of results from testing many other
Indigenous and non-white populations. Despite increased
testing for GDM in Greenland, compared to 2008, GDM
is most likely still under-diagnosed in Greenland.
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